TLR4 and neoplasm: Intratumoral injections of G100 resulted in an overall response rate of 33.3% and abscopal tumor regression in 72.2% of follicular lymphoma patients (NCT02501473).551 Additionally, G100 has been shown to induce antitumor immune responses and tumor regression in Merkel cell carcinoma patients.552 Other TLR4 agonists, such as HSPPC-96, a heat shock protein derived from patient GBM cells, may improve the prognosis of newly diagnosed GBM patients.